← All trials
NCT03096782
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2017
- Primary completion
- Jun 1, 2020
- Completion date
- Jun 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 25
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- University of Texas at HoustonLead sponsor
- University of Texas at HoustonOverall official - principal investigator
- Mesoblast, Inc.Collaborator
Drugs studied
Indications studied
- Histiocytosis, Langerhans-Cell
- Hodgkin Disease
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Biphenotypic, Acute
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Acute
- Leukemia, Myelomonocytic, Chronic
- Neoplasm, Residual
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Drug-Related Side Effects and Adverse Reactions
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.